

InvestTech
Advanced
Solutions




AGING
ANALYTICS
AGENCY

Longevity Industry Investment

Landscape Overview
Q1 2025

THE LONGEVITY ECONOMY ON A GLOBAL SCALE

Longevity Economy Scale Projections by Beginning of 2025




The Longevity Economy's Scale Projections contains global healthcare spending affecting Longevity, the combined capitalisation of publicly listed Longevity companies, the capitalisation of Longevity-related insurance and reinsurance companies, banks and pension funds and privately held Longevity companies.

Not only does ageing pose one of the most acute problems of our time - it also presents one of the most promising opportunities. Financial institutions, such as investment banks, pension funds, and insurance companies can either sink or swim when hit by the oncoming Silver Tsunami. Whether they will succeed in riding the wave or end up drowning under it will depend not only on their willingness to deploy new business models adapted to population ageing and emerging industries of AgeTech, WealthTech, and Longevity Finance, but also on the quality of Longevity analytics that they use to develop such business models.

We define the Longevity Industry as a combination of ageing, advanced preventive precision biomedicine, AgeTech, relevant parts of national healthcare budgets, and the global financial industry related to such sub-industries.

GLOBAL LONGEVITY ECOSYSTEM 2025



LONGEVITY INDUSTRY: MULTI-TRILLION DOLLAR OPPORTUNITY



FINANCIAL
TIMES

"The one billion retired people globally are a multi-trillion dollar opportunity for business "

~ Dmitry Kaminskiy, [interview in the Financial Times](#)

"We expect to add 1 billion older individuals in the next three to four decades, atop the more than 700 million older people we have today "

~ *International Monetary Fund*



LONGEVITY INDUSTRY: MULTI-TRILLION DOLLAR OPPORTUNITY

**The Global Longevity Market was estimated at
\$28 trillion in 2023**

50,000+ companies
(incl. 500 listed companies)

1,000+ R&D hubs

9,000+ investors

**1,000+ financial
institutions**

100+ governments

160 subsectors

The Longevity market is not only limited to anti-ageing applications of life sciences. It also includes some new sectors of the financial industry, as well as government projects (national Longevity development plans); hence, its overall size potentially exceeds \$28 trillion. As the majority of full-blown Longevity startups are quickly becoming mature companies, large institutional investors are making increasingly more investments in the industry and a full-fledged Longevity infrastructure is emerging.

There are at least 500 publicly traded corporations that can be considered part of the Longevity industry.

Longevity Biomedicine, FinTech, and AgeTech industries include 50,000+ companies, 9,000+ investors, 20 sectors, and 160 subsectors.


The Longevity Financial Industry includes 1,000+ corporations, 15 sectors, and 50 subsectors.

The Longevity Governance Landscape includes national healthcare budgets and development plans of at least 100 governments.

Note: Since there is no generally accepted methodology for their estimation, the numbers presented in the scheme are approximate.

LONGEVITY AND SILVER TSUNAMI - COLLISION OF TWO OPPOSING MEGATRENDS

Two Opposed MegaTrends




Rapid progress in biomedicine has been mainly due to the advances in collection and analysis of data. The industry is poised to witness a quantum leap in the near future, particularly because of the impact made by Artificial Intelligence on biomedicine R&D and in light of the upcoming paradigm shift from treatment to prevention.

At the same time, the inevitable Silver Tsunami (demographic ageing) places a major economic burden not only on the healthcare systems of developing nations, but also on major financial institutions, including pension funds, insurance companies, asset management firms and retail/private wealth banks. It is also expected to increase costs associated with old age.

Geographic Distribution of Investors in 2025

This chart represents the top 5 countries where Longevity Industry companies have received the biggest total investments as of Q1 2024. The USA, being the leader by size of total investments, showed the highest growth rate, (20%) which may indicate rising market among US-based companies, however, compared to 2022 the growth rate would be still negative. China, on the other hand, as the second biggest country by total investments, has shown a third compound growth rate of 15%, while the UK showed 18%; Canada experienced the smallest growth among this top 5 countries, having less than 10% increase, while Germany showed 13%.

Compound Annual Growth Rate of Investments in the Top 5 Longevity Countries by Investment Size in 2023-2024




Leading Investments

The regional distribution among investment targets of competing funds is consistent with the overall distribution of Longevity-related companies.

Interestingly, although many Big Pharma companies are located in the EU, the total number of investment targets in this region is quite small.

This is due to the novelty of the Longevity Industry, with the United States leading globally by the number of HealthTech and healthcare start-ups. Because of legal obstacles in the region, the number of Asia-based investment targets is quite small.

Longevity Industry Portfolio Funding



Top 20 Publicly Traded Longevity-Focused Companies

NASDAQ



US-Based



UnitedHealth Group
(UNH)
Market Cap: \$500B



Amgen Inc. (AMGN)
Market Cap: \$150B



Gilead Sciences, Inc.
(GILD)
Market Cap: \$100B



Regeneron
Pharmaceuticals, Inc.
(REGN)
Market Cap: \$85B



Vertex
Pharmaceuticals
Incorporated (VRTX)
Market Cap: \$90B



Biogen Inc. (BIIB)
Market Cap: \$50B



Moderna, Inc. (MRNA)
Market Cap: \$60B



China-Based



BeiGene (BGNE)
Market Cap: \$20B



UK-Based



Abcam (ABCM)
Market Cap: \$4B



AstraZeneca PLC (AZN)
Market Cap: \$200B

Euronext Brussel (BR)



Switzerland-Based



Novartis AG (NVS)
Market Cap: \$200B



Sanofi (SNY)
Market Cap: \$120B



Sweden-Based



Getinge (GETI-B)
Market Cap: \$10B

Hong Kong (HKD)



Hong Kong-Based



CRISPR Therapeutics AG
(CRSP)
Market Cap: \$7B



Deep Longevity
Acquired by \$4M

NYSE



US-Based



Pfizer Inc. (PFE)
Market Cap: \$220B



Eli Lilly and Company
(LLY)
Market Cap: \$400B

Other



US-Based



Alnylam
Pharmaceuticals, Inc.
(ALNY)
Market Cap: \$30B



Editas Medicine, Inc.
(EDIT)
Market Cap: \$5B




Sweden-Based



Roche Holding AG
(RHHBY)
Market Cap: \$300B

Longevity Investment Analytics Dashboard



 182,400
Companies 102,000
Investors 6,400
Longevity Organizations 35,700
Leaders

Dashboards

Longevity International ...

Longevity Club Analysis

Longevity Investment

Longevity Financial Das...

Data

Companies

Investors

Hubs

Longevity Organizations

Clinical Trials

Funding Rounds

Impact Investors

Venture Funds

Books

LONGEVITY INDUSTRY ...

BIOMARKERS OF HUMA...

LONGEVITY FINANCIAL I...

Data Room

Downloadable

Macroparameters




Industry SWOT Analysis




Analytical Reports Library



Longevity Industry Landscape



Network Diagrams



General AI Pharma Market Analysis

 500
Hubs 4,775,000
Data Points 9
Super Industries 48
IndustriesCCQQ Assessment T... [Pro](#)Automated SWOT A... [Pro](#)Operational Environ... [Pro](#)Comperative Analys... [Pro](#)Industry Heatmap C... [Pro](#)Automated Benchm... [Pro](#)Automated Chart B... [Pro](#)Cluster Analysis Tool [Pro](#)Competitor Analysis... [Pro](#)Topic Oriented Sub ... [Pro](#)Automared Industry... [Pro](#)DataRoom Navigati... [Pro](#)Interactive Entities ... [Pro](#)Interactive Leads Da... [Pro](#)Individual Leads Pro... [Pro](#)Individual Entities P... [Pro](#)Evolution Tree Cons... [Pro](#)Events Monitroing T... [Pro](#)Indices Builder and ... [Pro](#)Industry Universe A... [Pro](#)Interactive Framew... [Pro](#)Investor Relations A... [Pro](#)market Prediction a... [Pro](#)

Forms of Proposed Cooperation

Deep Knowledge Group offers a variety of collaboration and cooperation options for parties seeking to enhance their strategic decision making, corporate and operational intelligence, and tactical execution capabilities by accessing one or more of our 70+ health and life sciences-focused Big Data Analytical Dashboards and Market Intelligence Systems.

We offer access to our Dashboards across 3 tiers: Subscription (baseline access to tools and components), White Label Solution (access to full scope of features with certain degrees of customization, personalization and plug-and-play feature selection), and Custom Dashboard Creation (end-to-end customized solution tailored to your specific operational needs and requirements).

Big Data Analytics Dashboard Subscription

- Subscription access is the most economical option for parties seeking to utilize our dashboards
- Offers full scope of ready-for-use analytics, corporate and competitive intelligence, market monitoring and benchmarking tools
- Discounted rates for multi-dashboard access available.

Big Data Analytics Dashboard White Label Solution

- Enhanced access to a wider scope of Dashboard features and functionality
- Includes a certain degree of client-directed Dashboard component and functionality customization and personalization and plug-and-play feature selection
- Highly flexible choice of data sources

Custom Market Intelligence Dashboard Creation

- End-to-end custom solution tailored to the operational and organizational needs and specifics of the client
- Plug-and-play feature selection
- Ground-up custom design of new components according to client need
- Most versatile, customizable and sophisticated option available

We are open to a mutually beneficial cooperation



analytics@longevity.group

info@invest-solutions.tech

www.longevity.group/analytics

www.invest-solutions.tech

Aging Analytics Agency (AAA) & InvestTech Advanced Solutions (ITAS) Disclaimer

The information and opinions in this report were prepared by Aging Analytics Agency and InvestTech Advanced Solutions. The information herein is believed by AAA and ITAS to be reliable but AAA and ITAS make no representation as to the accuracy or completeness of such information. There is no guarantee that the views and opinions expressed in this communication will come to pass. AAA and ITAS may provide, may have provided or may seek to provide advisory services to one or more companies mentioned herein. In addition, employees of AAA and ITAS may have purchased or may purchase securities in one or more companies mentioned in this report. Opinions, estimates and analyses in this report constitute the current judgment of the author as of the date of this report. They do not necessarily reflect the opinions of AAA and ITAS and are subject to change without notice. AAA and ITAS have no obligation to update, modify or amend this report or to otherwise notify a reader thereof in the event that any matter stated herein, or any opinion, estimate, forecast or analysis set forth herein, changes or subsequently becomes inaccurate. This report is provided for informational purposes only. It is not to be construed as an offer to buy or sell or a solicitation of an offer to buy or sell any financial instruments or to participate in any particular trading strategy in any jurisdiction.